NASDAQ · Biotechnology

BioCardia, Inc. (BCDA) Stock

$0.84 -1.11% NASDAQ: BCDA Healthcare

BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments.

Valuation

MetricValue
Price$0.84
Market Cap$4.88M
P/E Ratio-0.83
P/B Ratio-8.62
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$2.38
52-Week Low$0.78
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-800.00%
ROA-454.15%
ROCE733.40%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-0.39
Current Ratio1.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$1.0M$0$0$0
Operating Profit$-13.0M$-12.0M$-12.0M$-8.0M$-8.0M
Net Profit$-13.0M$-12.0M$-12.0M$-8.0M$-8.0M
EPS$-11.19$-10.05$-8.19$-2.90$-1.23
Op Margin-1244.3%-880.3%-2441.1%-13794.8%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$16.0M$10.0M$3.0M$4.0M$3.0M
Total Liabilities$5.0M$5.0M$5.0M$3.0M$3.0M
Cash$13.0M$7.0M$1.0M$2.0M$2.0M
Borrowings$2.0M$2.0M$1.0M$1.0M$1.0M

Latest News

Daily – Vickers Top Insider Picks for 07/22/2026 Argus Research · Jul 22, 2026 Daily – Vickers Top Insider Picks for 07/21/2026 Argus Research · Jul 21, 2026 New Strong Sell Stocks for July 14th Zacks · Jul 14, 2026 BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities GlobeNewswire · Jun 18, 2026 BioCardia Announces $4.4 Million Financing GlobeNewswire · Jun 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-10.0M$-11.0M$-10.0M$-8.0M$-7.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$-1.0M$-1.0M$0
Net Cash Flow$-9.0M$-6.0M$-6.0M$1.0M$0
Free Cash Flow$-10.0M$-11.0M$-10.0M$-8.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-0.56
FCF Yield-143.59%
Quick Ratio1.50
Interest Coverage0.00
Return 1Y-61.57%
Return 3Y-97.49%
Return 5Y-98.27%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACXP $1.40 -1.40% -0.36 $2.22M 0.00%
ADIL $3.33 +1.22% -1.14 $3.20M 0.00%
ALZN $1.35 +0.75% -0.11 $5.14M 0.00%
APRE $0.62 -1.16% -0.47 $4.06M 0.00%
APVO $4.21 -4.10% -0.06 $9.21M 0.00%

About BioCardia, Inc.

BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.

BioCardia, Inc. is led by CEO Peter A. Altman, employs 17 people, headquartered in US, publicly traded since 1996.

BioCardia, Inc. (BCDA) stock trades at $0.84 with a market capitalization of $4.88M. The stock is valued at a price-to-earnings (P/E) ratio of -0.83, price-to-book of -8.62, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.78 and $2.38, and currently trades 64.7% below its 52-week high.

On profitability, BioCardia, Inc. generates a return on equity (ROE) of -800.00%, return on capital employed of 733.40%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.biocardia.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides